Related Experiment Video
Updated: May 17, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Managing adverse effects of interferon-alfa and ribavirin in combination therapy for HCV
Jihad Slim1, Muhammad Shoaib Afridi
1St. Michaels Medical Center, 111 Central Avenue, Newark, NJ 07102, USA. jsmdsmmc@gmail.com
Abstract:
This article focuses on the adverse effects of hepatitis C therapy, which includes pegylated interferon alfa-2a or -2b with ribavirin. The hepatitis C virus provider should remain cognizant of the various organ systems that can be affected, which adverse effects should be addressed with the help of an expert, and the presentation of symptoms as they occur throughout the course of therapy. A systems-based approach should help to characterize the nature of the adverse effects that patients experience, and also to determine when patients should be further investigated by a consultant.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Hepatitis
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

